The Purpose of the Study is to Evaluate the Safety, Tolerability and Pharmacokinetics of Single-ascending and Multiple-ascending Doses of GIM-407
- First Posted Date
- 2024-08-02
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Georgiamune Inc
- Target Recruit Count
- 80
- Registration Number
- NCT06536101
- Locations
- ๐ฆ๐บ
Nucleus Network Pty Ltd, Melbourne, Victoria, Australia
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Melanoma Stage IVSolid Tumor
- Interventions
- Drug: Anti-PD-1 monoclonal antibody
- First Posted Date
- 2024-05-23
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Georgiamune Inc
- Target Recruit Count
- 117
- Registration Number
- NCT06425926
- Locations
- ๐บ๐ธ
University of Cincinnati Cancer Center, Cincinnati, Ohio, United States
๐บ๐ธTennessee Oncology, PLLC, Nashville, Tennessee, United States
๐บ๐ธHonor Health Research Institute, Scottsdale, Arizona, United States
Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies
- First Posted Date
- 2023-09-07
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Georgiamune Inc
- Target Recruit Count
- 111
- Registration Number
- NCT06028074
- Locations
- ๐บ๐ธ
The Angeles Clinic and Research Institute, Los Angeles, California, United States
๐บ๐ธUSC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
๐บ๐ธUCLA Hematology/Oncology, Los Angeles, California, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath